Alvotech Lines Up FDA Inspection Ahead Of Adalimumab Action

Reinspection Of Reykjavik Plant Scheduled For 6 March, Ahead Of 13 April Goal Date

Alvotech has secured a US FDA reinspection of its Reykjavik plant in March, ahead of the agency’s April goal date for action on the firm’s pending application for a high-concentration, interchangeable adalimumab biosimilar rival to Humira.

6 March calendar date with red pin
An FDA inspection of the Reykjavik plant is scheduled for 6 March • Source: Shutterstock

Biosimilars developer Alvotech has received a favorable update from the US Food and Drug Administration indicating that the agency will re-inspect the firm’s Reykjavik facility well ahead of an April FDA goal date for Alvotech’s AVT02 proposed interchangeable high-concentration adalimumab biosimilar.

Alvotech’s filing for the biosimilar had previously been held up by a complete response letter from the FDA. (Also see...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.